2031년까지 글로벌 및 폴란드 암 치료제 시장 전망

Global & Poland Cancer Therapeutics Market to 2031

상품코드Philippines Cancer Therapeutics Market.pdf
발행기관Business Market Insights
발행일2025.05.26
페이지 수100 Pages
포맷PDF
커버리지Country

₩3,600,000 – ₩6,600,000

보고서 요약(국문)

폴란드의 암 치료제 시장은 암 발병 건수 증가와 치료 기술의 지속적인 발전으로 인해 빠르게 성장하고 있습니다. 암은 여전히 ​​폴란드에서 주요 사망 원인 중 하나입니다. 2021년 폴란드 국립 암 등록소는 약 171,558건의 새로운 암 진단과 93,652건의 암 관련 사망을 보고했습니다. 또한 스페인 암 등록 네트워크의 자료에 따르면 같은 해 폴란드에서 약 8,805건의 유방암 사망이 발생했습니다. 이러한 질병 부담의 증가는 더욱 혁신적이고 효과적인 암 치료법에 대한 수요를 촉진하고 있습니다.

암이 초래하는 심각한 건강 및 사회경제적 영향을 해결하기 위해 폴란드 정부는 여러 가지 주요 정책을 도입했습니다. 보건부는 예방, 조기 진단 및 치료 결과 개선을 통해 암 발생률과 사망률을 낮추기 위한 국가 암 관리 프로그램(NCCP)을 시작했습니다. 2020년 4월에는 기존의 국가 암 질환 관리 프로그램(2016~2024)을 대체하는 국가 암 전략 2020~2030이 시행되었습니다. 이번에 새롭게 개정된 전략은 폴란드의 암 치료 개선을 위한 포괄적인 틀을 제공하며, 유럽의 암 극복 계획(Beating Cancer Plan)과 긴밀하게 연계되어 있습니다. 핵심 목표는 5년 생존율 향상, 조기 발견 촉진, 그리고 치료 중 및 치료 후 환자의 삶의 질 향상입니다.

보고서 요약(영어 원문)

Poland’s cancer therapeutics market is expanding rapidly, driven by a growing number of cancer cases and ongoing advancements in treatment technologies. Cancer remains one of the leading causes of death in the country. In 2021, the Polish National Cancer Registry reported around 171,558 new cancer diagnoses and 93,652 cancer-related deaths. Additionally, data from the Spanish Network of Cancer Registries indicates that around 8,805 breast cancer deaths occurred in Poland that same year. This rising disease burden is fueling the demand for more innovative and effective cancer therapies.

To address the significant health and socioeconomic impact of cancer, the Polish government has introduced several key initiatives. The Ministry of Health launched the National Cancer Control Program (NCCP) to lower cancer incidence and mortality rates through prevention, early diagnosis, and enhanced treatment outcomes. In April 2020, the National Cancer Strategy 2020–2030 was implemented, replacing the earlier National Programme for Cancer Diseases Control (2016–2024). This updated strategy offers a comprehensive framework for improving cancer care in Poland and is closely aligned with Europe’s Beating Cancer Plan. Its core goals include increasing five-year survival rates, promoting early detection, and enhancing the quality of life for patients during and after treatment.

상세 목차

TABLE OF CONTENTS

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation:

4. Poland Cancer Therapeutics Market Landscape

4.1 Overview

4.2 Ecosystem Analysis

4.2.1 List of Vendors in the Value Chain

5. Cancer Therapeutics Market Key Market Dynamics

5.1 Cancer Therapeutics Market – Key Market Dynamics

5.2 Market Drivers

5.3 Market Restraints

5.4 Market Opportunities

5.5 Future Trends

5.6 Impact of Drivers and Restraints

6. Poland Cancer Therapeutics Market – Analysis

6.1 Poland Cancer Therapeutics Market Revenue (US$ Million), 2021–2031

6.2 Poland Cancer Therapeutics Market Revenue and Forecast Analysis

7. Poland Cancer Therapeutics Market Analysis – by Therapy Types

7.1 Poland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types

8. Poland Cancer Therapeutics Market Analysis – by Indications

8.1 Poland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications

9. Poland Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Poland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players

10.1 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.2 Partnerships and Collaborations

11.2 Other Developments

12. Company Profiles

12.1 Bristol-Myers Squibb Co

12.1. 1 Key Facts

12.1. 2 Business Description

12.1. 3 Products and Services

12.1. 4 Financial Overview

12.1. 5 SWOT Analysis

12.1. 6 Key Developments

12.2 AbbVie Inc

12.2. 1 Key Facts

12.2. 2 Business Description

12.2. 3 Products and Services

12.2. 4 Financial Overview

12.2. 5 SWOT Analysis

12.2. 6 Key Developments

12.3 Johnson & Johnson

12.3. 1 Key Facts

12.3. 2 Business Description

12.3. 3 Products and Services

12.3. 4 Financial Overview

12.3. 5 SWOT Analysis

12.3. 6 Key Developments

12.4 F. Hoffmann-La Roche Ltd

12.4. 1 Key Facts

12.4. 2 Business Description

12.4. 3 Products and Services

12.4. 4 Financial Overview

12.4. 5 SWOT Analysis

12.4. 6 Key Developments

12.5 Pfizer Inc

12.5. 1 Key Facts

12.5. 2 Business Description

12.5. 3 Products and Services

12.5. 4 Financial Overview

12.5. 5 SWOT Analysis

12.5. 6 Key Developments

12.6 AstraZeneca Plc

12.6. 1 Key Facts

12.6. 2 Business Description

12.6. 3 Products and Services

12.6. 4 Financial Overview

12.6. 5 SWOT Analysis

12.6. 6 Key Developments

12.7 Merck KGaA

12.7. 1 Key Facts

12.7. 2 Business Description

12.7. 3 Products and Services

12.7. 4 Financial Overview

12.7. 5 SWOT Analysis

12.7. 6 Key Developments

12.8 Novartis AG

12.8. 1 Key Facts

12.8. 2 Business Description

12.8. 3 Products and Services

12.8. 4 Financial Overview

12.8. 5 SWOT Analysis

12.8. 6 Key Developments

12.9 Astellas Pharma Inc

12.9. 1 Key Facts

12.9. 2 Business Description

12.9. 3 Products and Services

12.9. 4 Financial Overview

12.9. 5 SWOT Analysis

12.9. 6 Key Developments

12.10 Eli Lilly and Co

12.10. 1 Key Facts

12.10. 2 Business Description

12.10. 3 Products and Services

12.10. 4 Financial Overview

12.10. 5 SWOT Analysis

12.10. 6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

언급된 주요 기업들

TABLE OF COMPANIES

1. Bristol-Myers Squibb Co

2. AbbVie Inc

3. Johnson & Johnson

4. F. Hoffmann-La Roche Ltd

5. Pfizer Inc

6. AstraZeneca Plc

7. Merck KGaA

8. Novartis AG

9. Astellas Pharma Inc

10. Eli Lilly and Co

표 목록 (Tables)

TABLE OF TABLES

Table 1. Poland Cancer Therapeutics Market Segmentation

Table 2. List of Vendors

Table 3. Poland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)

Table 4. Poland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)

Table 5. Poland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types

Table 6. Poland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types

Table 7. Poland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications

Table 8. Poland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications

Table 9. Poland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel

Table 10. Poland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel

Table 11. List of Abbreviations

그림 목록 (Figures)

TABLE OF FIGURES

Figure 1. Impact Analysis of Drivers and Restraints

Figure 2. Poland Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031

Figure 3. Heat Map Analysis by Key Players

Figure 4. Company Positioning and Concentration